Erasca, Inc. (ERAS) Stock Competitors & Peer Comparison
See (ERAS) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ERAS | $20.47 | +14.36% | 6.1B | -44.32 | -$0.44 | N/A |
| VRTX | $475.20 | -1.05% | 120.9B | 25.31 | $18.82 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| REGN | $664.50 | +0.21% | 67.6B | 14.38 | $45.63 | +0.55% |
| ARGX | $862.58 | -1.56% | 53.4B | 77.57 | $11.08 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMDW | $8.90 | -0.67% | 39.9B | -2.20 | -$4.15 | N/A |
| RVMD | $183.32 | -0.34% | 39.3B | -26.16 | -$7.07 | N/A |
| ALNY | $283.09 | -1.72% | 37.6B | 50.68 | $5.55 | N/A |
| ONC | $312.75 | +2.89% | 32.8B | 68.58 | $4.47 | N/A |
Stock Comparison
ERAS vs VRTX Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, VRTX has a market cap of 120.9B. Regarding current trading prices, ERAS is priced at $20.47, while VRTX trades at $475.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas VRTX's P/E ratio is 25.31. In terms of profitability, ERAS's ROE is -0.77%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, ERAS is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check VRTX's competition here
ERAS vs VRNA Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, ERAS is priced at $20.47, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas VRNA's P/E ratio is -102.80. In terms of profitability, ERAS's ROE is -0.77%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, ERAS is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check VRNA's competition here
ERAS vs REGN Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, REGN has a market cap of 67.6B. Regarding current trading prices, ERAS is priced at $20.47, while REGN trades at $664.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas REGN's P/E ratio is 14.38. In terms of profitability, ERAS's ROE is -0.77%, compared to REGN's ROE of +0.14%. Regarding short-term risk, ERAS is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check REGN's competition here
ERAS vs ARGX Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, ARGX has a market cap of 53.4B. Regarding current trading prices, ERAS is priced at $20.47, while ARGX trades at $862.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas ARGX's P/E ratio is 77.57. In terms of profitability, ERAS's ROE is -0.77%, compared to ARGX's ROE of +0.22%. Regarding short-term risk, ERAS is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check ARGX's competition here
ERAS vs SGEN Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, ERAS is priced at $20.47, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas SGEN's P/E ratio is -57.19. In terms of profitability, ERAS's ROE is -0.77%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, ERAS is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check SGEN's competition here
ERAS vs RVMDW Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, RVMDW has a market cap of 39.9B. Regarding current trading prices, ERAS is priced at $20.47, while RVMDW trades at $8.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas RVMDW's P/E ratio is -2.20. In terms of profitability, ERAS's ROE is -0.77%, compared to RVMDW's ROE of -0.83%. Regarding short-term risk, ERAS is more volatile compared to RVMDW. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check RVMDW's competition here
ERAS vs RVMD Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, RVMD has a market cap of 39.3B. Regarding current trading prices, ERAS is priced at $20.47, while RVMD trades at $183.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas RVMD's P/E ratio is -26.16. In terms of profitability, ERAS's ROE is -0.77%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, ERAS is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check RVMD's competition here
ERAS vs ALNY Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, ALNY has a market cap of 37.6B. Regarding current trading prices, ERAS is priced at $20.47, while ALNY trades at $283.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas ALNY's P/E ratio is 50.68. In terms of profitability, ERAS's ROE is -0.77%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, ERAS is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check ALNY's competition here
ERAS vs ONC Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, ONC has a market cap of 32.8B. Regarding current trading prices, ERAS is priced at $20.47, while ONC trades at $312.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas ONC's P/E ratio is 68.58. In terms of profitability, ERAS's ROE is -0.77%, compared to ONC's ROE of +0.12%. Regarding short-term risk, ERAS is more volatile compared to ONC. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check ONC's competition here
ERAS vs MRNA Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, MRNA has a market cap of 26.8B. Regarding current trading prices, ERAS is priced at $20.47, while MRNA trades at $67.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas MRNA's P/E ratio is -8.27. In terms of profitability, ERAS's ROE is -0.77%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, ERAS is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check MRNA's competition here
ERAS vs ROIV Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, ROIV has a market cap of 25.1B. Regarding current trading prices, ERAS is priced at $20.47, while ROIV trades at $34.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas ROIV's P/E ratio is -35.88. In terms of profitability, ERAS's ROE is -0.77%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, ERAS is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check ROIV's competition here
ERAS vs INSM Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, INSM has a market cap of 23.9B. Regarding current trading prices, ERAS is priced at $20.47, while INSM trades at $109.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas INSM's P/E ratio is -19.15. In terms of profitability, ERAS's ROE is -0.77%, compared to INSM's ROE of -1.30%. Regarding short-term risk, ERAS is more volatile compared to INSM. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check INSM's competition here
ERAS vs INCY Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, INCY has a market cap of 23B. Regarding current trading prices, ERAS is priced at $20.47, while INCY trades at $113.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas INCY's P/E ratio is 15.44. In terms of profitability, ERAS's ROE is -0.77%, compared to INCY's ROE of +0.29%. Regarding short-term risk, ERAS is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check INCY's competition here
ERAS vs BNTX Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, BNTX has a market cap of 22.9B. Regarding current trading prices, ERAS is priced at $20.47, while BNTX trades at $90.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas BNTX's P/E ratio is -19.57. In terms of profitability, ERAS's ROE is -0.77%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, ERAS is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check BNTX's competition here
ERAS vs UTHR Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, UTHR has a market cap of 22.4B. Regarding current trading prices, ERAS is priced at $20.47, while UTHR trades at $530.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas UTHR's P/E ratio is 19.44. In terms of profitability, ERAS's ROE is -0.77%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, ERAS is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check UTHR's competition here
ERAS vs BGNE Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, ERAS is priced at $20.47, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas BGNE's P/E ratio is -22.55. In terms of profitability, ERAS's ROE is -0.77%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, ERAS is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check BGNE's competition here
ERAS vs DNA-WT Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, ERAS is priced at $20.47, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, ERAS's ROE is -0.77%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, ERAS is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for ERAS.Check DNA-WT's competition here
ERAS vs GMAB Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, GMAB has a market cap of 17.6B. Regarding current trading prices, ERAS is priced at $20.47, while GMAB trades at $29.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas GMAB's P/E ratio is 20.67. In terms of profitability, ERAS's ROE is -0.77%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, ERAS is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check GMAB's competition here
ERAS vs NBIX Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, NBIX has a market cap of 17.3B. Regarding current trading prices, ERAS is priced at $20.47, while NBIX trades at $171.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas NBIX's P/E ratio is 24.85. In terms of profitability, ERAS's ROE is -0.77%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, ERAS is more volatile compared to NBIX. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check NBIX's competition here
ERAS vs ASND Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, ASND has a market cap of 16.5B. Regarding current trading prices, ERAS is priced at $20.47, while ASND trades at $264.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas ASND's P/E ratio is -109.74. In terms of profitability, ERAS's ROE is -0.77%, compared to ASND's ROE of -56.42%. Regarding short-term risk, ERAS is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check ASND's competition here
ERAS vs BBIO Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, BBIO has a market cap of 16.5B. Regarding current trading prices, ERAS is priced at $20.47, while BBIO trades at $82.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas BBIO's P/E ratio is -22.48. In terms of profitability, ERAS's ROE is -0.77%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, ERAS is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check BBIO's competition here
ERAS vs JAZZ Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, JAZZ has a market cap of 15B. Regarding current trading prices, ERAS is priced at $20.47, while JAZZ trades at $238.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas JAZZ's P/E ratio is 18.51. In terms of profitability, ERAS's ROE is -0.77%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, ERAS is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check JAZZ's competition here
ERAS vs EXEL Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, EXEL has a market cap of 14B. Regarding current trading prices, ERAS is priced at $20.47, while EXEL trades at $55.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas EXEL's P/E ratio is 16.70. In terms of profitability, ERAS's ROE is -0.77%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, ERAS is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check EXEL's competition here
ERAS vs KRTX Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, ERAS is priced at $20.47, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas KRTX's P/E ratio is -28.09. In terms of profitability, ERAS's ROE is -0.77%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, ERAS is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check KRTX's competition here
ERAS vs MDGL Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, MDGL has a market cap of 12.4B. Regarding current trading prices, ERAS is priced at $20.47, while MDGL trades at $541.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas MDGL's P/E ratio is -41.94. In terms of profitability, ERAS's ROE is -0.77%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, ERAS is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check MDGL's competition here
ERAS vs AXSM Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, AXSM has a market cap of 12.1B. Regarding current trading prices, ERAS is priced at $20.47, while AXSM trades at $232.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas AXSM's P/E ratio is -61.43. In terms of profitability, ERAS's ROE is -0.77%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, ERAS is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check AXSM's competition here
ERAS vs SMMT Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, SMMT has a market cap of 12B. Regarding current trading prices, ERAS is priced at $20.47, while SMMT trades at $15.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas SMMT's P/E ratio is -9.67. In terms of profitability, ERAS's ROE is -0.77%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, ERAS is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check SMMT's competition here
ERAS vs BMRN Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, BMRN has a market cap of 11.3B. Regarding current trading prices, ERAS is priced at $20.47, while BMRN trades at $59.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas BMRN's P/E ratio is 28.19. In terms of profitability, ERAS's ROE is -0.77%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, ERAS is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check BMRN's competition here
ERAS vs RNAM Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, ERAS is priced at $20.47, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas RNAM's P/E ratio is -17.39. In terms of profitability, ERAS's ROE is -0.77%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, ERAS is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check RNAM's competition here
ERAS vs TECH Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, TECH has a market cap of 11.2B. Regarding current trading prices, ERAS is priced at $20.47, while TECH trades at $71.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas TECH's P/E ratio is 36.72. In terms of profitability, ERAS's ROE is -0.77%, compared to TECH's ROE of +0.05%. Regarding short-term risk, ERAS is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check TECH's competition here
ERAS vs CYTK Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, CYTK has a market cap of 10.2B. Regarding current trading prices, ERAS is priced at $20.47, while CYTK trades at $82.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas CYTK's P/E ratio is -14.05. In terms of profitability, ERAS's ROE is -0.77%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, ERAS is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check CYTK's competition here
ERAS vs ARWR Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, ARWR has a market cap of 10.1B. Regarding current trading prices, ERAS is priced at $20.47, while ARWR trades at $70.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas ARWR's P/E ratio is -33.45. In terms of profitability, ERAS's ROE is -0.77%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, ERAS is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check ARWR's competition here
ERAS vs KRYS Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, KRYS has a market cap of 10B. Regarding current trading prices, ERAS is priced at $20.47, while KRYS trades at $338.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas KRYS's P/E ratio is 45.38. In terms of profitability, ERAS's ROE is -0.77%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, ERAS is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check KRYS's competition here
ERAS vs ABVX Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, ABVX has a market cap of 9.9B. Regarding current trading prices, ERAS is priced at $20.47, while ABVX trades at $136.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas ABVX's P/E ratio is -70.72. In terms of profitability, ERAS's ROE is -0.77%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, ERAS is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check ABVX's competition here
ERAS vs CORT Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, CORT has a market cap of 9.7B. Regarding current trading prices, ERAS is priced at $20.47, while CORT trades at $86.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas CORT's P/E ratio is 258.49. In terms of profitability, ERAS's ROE is -0.77%, compared to CORT's ROE of +0.08%. Regarding short-term risk, ERAS is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check CORT's competition here
ERAS vs RXDX Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, ERAS is priced at $20.47, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas RXDX's P/E ratio is -56.47. In terms of profitability, ERAS's ROE is -0.77%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, ERAS is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check RXDX's competition here
ERAS vs KYMR Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, KYMR has a market cap of 9.2B. Regarding current trading prices, ERAS is priced at $20.47, while KYMR trades at $113.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas KYMR's P/E ratio is -31.75. In terms of profitability, ERAS's ROE is -0.77%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, ERAS is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check KYMR's competition here
ERAS vs NUVL Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, ERAS is priced at $20.47, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas NUVL's P/E ratio is -21.79. In terms of profitability, ERAS's ROE is -0.77%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, ERAS is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check NUVL's competition here
ERAS vs IONS Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, IONS has a market cap of 9.1B. Regarding current trading prices, ERAS is priced at $20.47, while IONS trades at $54.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas IONS's P/E ratio is -31.94. In terms of profitability, ERAS's ROE is -0.77%, compared to IONS's ROE of -0.59%. Regarding short-term risk, ERAS is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check IONS's competition here
ERAS vs HALO Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, HALO has a market cap of 8.9B. Regarding current trading prices, ERAS is priced at $20.47, while HALO trades at $75.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas HALO's P/E ratio is 16.24. In terms of profitability, ERAS's ROE is -0.77%, compared to HALO's ROE of +1.26%. Regarding short-term risk, ERAS is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check HALO's competition here
ERAS vs CRNX Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, CRNX has a market cap of 8.9B. Regarding current trading prices, ERAS is priced at $20.47, while CRNX trades at $83.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas CRNX's P/E ratio is -16.32. In terms of profitability, ERAS's ROE is -0.77%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, ERAS is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check CRNX's competition here
ERAS vs IMGN Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, ERAS is priced at $20.47, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas IMGN's P/E ratio is -111.55. In terms of profitability, ERAS's ROE is -0.77%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, ERAS is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check IMGN's competition here
ERAS vs ALKS Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, ALKS has a market cap of 8.6B. Regarding current trading prices, ERAS is priced at $20.47, while ALKS trades at $51.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas ALKS's P/E ratio is 54.32. In terms of profitability, ERAS's ROE is -0.77%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, ERAS is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check ALKS's competition here
ERAS vs PTGX Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, PTGX has a market cap of 8.4B. Regarding current trading prices, ERAS is priced at $20.47, while PTGX trades at $133.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas PTGX's P/E ratio is -72.52. In terms of profitability, ERAS's ROE is -0.77%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, ERAS is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check PTGX's competition here
ERAS vs TGTX Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, TGTX has a market cap of 8.4B. Regarding current trading prices, ERAS is priced at $20.47, while TGTX trades at $54.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas TGTX's P/E ratio is 18.86. In terms of profitability, ERAS's ROE is -0.77%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, ERAS is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check TGTX's competition here
ERAS vs BPMC Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, ERAS is priced at $20.47, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas BPMC's P/E ratio is -51.58. In terms of profitability, ERAS's ROE is -0.77%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, ERAS is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check BPMC's competition here
ERAS vs APGE Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, APGE has a market cap of 8.3B. Regarding current trading prices, ERAS is priced at $20.47, while APGE trades at $134.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas APGE's P/E ratio is -30.94. In terms of profitability, ERAS's ROE is -0.77%, compared to APGE's ROE of -0.33%. Regarding short-term risk, ERAS is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check APGE's competition here
ERAS vs IBRX Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, IBRX has a market cap of 8.3B. Regarding current trading prices, ERAS is priced at $20.47, while IBRX trades at $7.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas IBRX's P/E ratio is -24.62. In terms of profitability, ERAS's ROE is -0.77%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, ERAS is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check IBRX's competition here
ERAS vs CERE Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, ERAS is priced at $20.47, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas CERE's P/E ratio is -16.47. In terms of profitability, ERAS's ROE is -0.77%, compared to CERE's ROE of -0.72%. Regarding short-term risk, ERAS is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check CERE's competition here
ERAS vs PCVX Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, PCVX has a market cap of 8.1B. Regarding current trading prices, ERAS is priced at $20.47, while PCVX trades at $55.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas PCVX's P/E ratio is -8.17. In terms of profitability, ERAS's ROE is -0.77%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, ERAS is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check PCVX's competition here
ERAS vs IMVT Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, IMVT has a market cap of 8B. Regarding current trading prices, ERAS is priced at $20.47, while IMVT trades at $38.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas IMVT's P/E ratio is -14.52. In terms of profitability, ERAS's ROE is -0.77%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, ERAS is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check IMVT's competition here
ERAS vs RYTM Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, RYTM has a market cap of 7.5B. Regarding current trading prices, ERAS is priced at $20.47, while RYTM trades at $108.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas RYTM's P/E ratio is -35.13. In terms of profitability, ERAS's ROE is -0.77%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, ERAS is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check RYTM's competition here
ERAS vs MTSR Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, ERAS is priced at $20.47, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas MTSR's P/E ratio is -23.58. In terms of profitability, ERAS's ROE is -0.77%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, ERAS is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check MTSR's competition here
ERAS vs PRAX Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, PRAX has a market cap of 6.9B. Regarding current trading prices, ERAS is priced at $20.47, while PRAX trades at $320.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas PRAX's P/E ratio is -24.51. In terms of profitability, ERAS's ROE is -0.77%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, ERAS is more volatile compared to PRAX. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check PRAX's competition here
ERAS vs MRUS Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, ERAS is priced at $20.47, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas MRUS's P/E ratio is -17.05. In terms of profitability, ERAS's ROE is -0.77%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, ERAS is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check MRUS's competition here
ERAS vs LQDA Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, LQDA has a market cap of 6.8B. Regarding current trading prices, ERAS is priced at $20.47, while LQDA trades at $75.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas LQDA's P/E ratio is 546.36. In terms of profitability, ERAS's ROE is -0.77%, compared to LQDA's ROE of +0.47%. Regarding short-term risk, ERAS is more volatile compared to LQDA. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check LQDA's competition here
ERAS vs ACLX Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, ERAS is priced at $20.47, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas ACLX's P/E ratio is -28.27. In terms of profitability, ERAS's ROE is -0.77%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, ERAS is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check ACLX's competition here
ERAS vs COGT Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, COGT has a market cap of 6.6B. Regarding current trading prices, ERAS is priced at $20.47, while COGT trades at $38.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas COGT's P/E ratio is -18.25. In terms of profitability, ERAS's ROE is -0.77%, compared to COGT's ROE of -0.83%. Regarding short-term risk, ERAS is more volatile compared to COGT. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check COGT's competition here
ERAS vs RETA Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, ERAS is priced at $20.47, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas RETA's P/E ratio is -66.29. In terms of profitability, ERAS's ROE is -0.77%, compared to RETA's ROE of +0.47%. Regarding short-term risk, ERAS is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check RETA's competition here
ERAS vs PTCT Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, PTCT has a market cap of 6.5B. Regarding current trading prices, ERAS is priced at $20.47, while PTCT trades at $78.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas PTCT's P/E ratio is -33.50. In terms of profitability, ERAS's ROE is -0.77%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, ERAS is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check PTCT's competition here
ERAS vs SRRK Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, SRRK has a market cap of 6.4B. Regarding current trading prices, ERAS is priced at $20.47, while SRRK trades at $53.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas SRRK's P/E ratio is -14.98. In terms of profitability, ERAS's ROE is -0.77%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, ERAS is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check SRRK's competition here
ERAS vs CGON Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, CGON has a market cap of 6.3B. Regarding current trading prices, ERAS is priced at $20.47, while CGON trades at $73.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas CGON's P/E ratio is -30.80. In terms of profitability, ERAS's ROE is -0.77%, compared to CGON's ROE of -0.23%. Regarding short-term risk, ERAS is less volatile compared to CGON. This indicates potentially lower risk in terms of short-term price fluctuations for ERAS.Check CGON's competition here
ERAS vs CNTA Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, ERAS is priced at $20.47, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas CNTA's P/E ratio is -22.63. In terms of profitability, ERAS's ROE is -0.77%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, ERAS is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check CNTA's competition here
ERAS vs MIRM Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, MIRM has a market cap of 6.1B. Regarding current trading prices, ERAS is priced at $20.47, while MIRM trades at $118.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas MIRM's P/E ratio is -8.88. In terms of profitability, ERAS's ROE is -0.77%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, ERAS is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check MIRM's competition here
ERAS vs LGND Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, LGND has a market cap of 6B. Regarding current trading prices, ERAS is priced at $20.47, while LGND trades at $297.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas LGND's P/E ratio is 36.09. In terms of profitability, ERAS's ROE is -0.77%, compared to LGND's ROE of +0.16%. Regarding short-term risk, ERAS is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check LGND's competition here
ERAS vs SYRE Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, SYRE has a market cap of 6B. Regarding current trading prices, ERAS is priced at $20.47, while SYRE trades at $97.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas SYRE's P/E ratio is -47.57. In terms of profitability, ERAS's ROE is -0.77%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, ERAS is more volatile compared to SYRE. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check SYRE's competition here
ERAS vs BLTE Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, BLTE has a market cap of 5.9B. Regarding current trading prices, ERAS is priced at $20.47, while BLTE trades at $145.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas BLTE's P/E ratio is -78.44. In terms of profitability, ERAS's ROE is -0.77%, compared to BLTE's ROE of -0.18%. Regarding short-term risk, ERAS is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check BLTE's competition here
ERAS vs CDTX Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, ERAS is priced at $20.47, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas CDTX's P/E ratio is -19.77. In terms of profitability, ERAS's ROE is -0.77%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, ERAS is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check CDTX's competition here
ERAS vs ABCM Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, ERAS is priced at $20.47, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, ERAS's ROE is -0.77%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, ERAS is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check ABCM's competition here
ERAS vs ISEE Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, ERAS is priced at $20.47, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas ISEE's P/E ratio is -22.44. In terms of profitability, ERAS's ROE is -0.77%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, ERAS is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check ISEE's competition here
ERAS vs CELC Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, CELC has a market cap of 5.4B. Regarding current trading prices, ERAS is priced at $20.47, while CELC trades at $92.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas CELC's P/E ratio is -28.47. In terms of profitability, ERAS's ROE is -0.77%, compared to CELC's ROE of -2.45%. Regarding short-term risk, ERAS is less volatile compared to CELC. This indicates potentially lower risk in terms of short-term price fluctuations for ERAS.Check CELC's competition here
ERAS vs XENE Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, XENE has a market cap of 5.3B. Regarding current trading prices, ERAS is priced at $20.47, while XENE trades at $67.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas XENE's P/E ratio is -14.32. In terms of profitability, ERAS's ROE is -0.77%, compared to XENE's ROE of -0.49%. Regarding short-term risk, ERAS is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check XENE's competition here
ERAS vs TVTX Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, TVTX has a market cap of 5.3B. Regarding current trading prices, ERAS is priced at $20.47, while TVTX trades at $56.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas TVTX's P/E ratio is -259.36. In terms of profitability, ERAS's ROE is -0.77%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, ERAS is more volatile compared to TVTX. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check TVTX's competition here
ERAS vs APLS Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, ERAS is priced at $20.47, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas APLS's P/E ratio is 38.35. In terms of profitability, ERAS's ROE is -0.77%, compared to APLS's ROE of +0.40%. Regarding short-term risk, ERAS is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check APLS's competition here
ERAS vs DFTX Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, DFTX has a market cap of 5B. Regarding current trading prices, ERAS is priced at $20.47, while DFTX trades at $45.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas DFTX's P/E ratio is N/A. In terms of profitability, ERAS's ROE is -0.77%, compared to DFTX's ROE of -1.02%. Regarding short-term risk, ERAS is more volatile compared to DFTX. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check DFTX's competition here
ERAS vs CRSP Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, CRSP has a market cap of 4.9B. Regarding current trading prices, ERAS is priced at $20.47, while CRSP trades at $50.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas CRSP's P/E ratio is -9.87. In terms of profitability, ERAS's ROE is -0.77%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, ERAS is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check CRSP's competition here
ERAS vs CAI Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, CAI has a market cap of 4.8B. Regarding current trading prices, ERAS is priced at $20.47, while CAI trades at $17.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas CAI's P/E ratio is -93.23. In terms of profitability, ERAS's ROE is -0.77%, compared to CAI's ROE of +0.06%. Regarding short-term risk, ERAS is more volatile compared to CAI. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check CAI's competition here
ERAS vs TERN Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, ERAS is priced at $20.47, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas TERN's P/E ratio is -51.41. In terms of profitability, ERAS's ROE is -0.77%, compared to TERN's ROE of -0.20%. Regarding short-term risk, ERAS is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check TERN's competition here
ERAS vs LEGN Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, LEGN has a market cap of 4.7B. Regarding current trading prices, ERAS is priced at $20.47, while LEGN trades at $23.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas LEGN's P/E ratio is -37.75. In terms of profitability, ERAS's ROE is -0.77%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, ERAS is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for ERAS.Check LEGN's competition here
ERAS vs MANE Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, MANE has a market cap of 4.6B. Regarding current trading prices, ERAS is priced at $20.47, while MANE trades at $124.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas MANE's P/E ratio is -34.99. In terms of profitability, ERAS's ROE is -0.77%, compared to MANE's ROE of -0.84%. Regarding short-term risk, ERAS is less volatile compared to MANE. This indicates potentially lower risk in terms of short-term price fluctuations for ERAS.Check MANE's competition here
ERAS vs FOLD Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, ERAS is priced at $20.47, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas FOLD's P/E ratio is -161.00. In terms of profitability, ERAS's ROE is -0.77%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, ERAS is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check FOLD's competition here
ERAS vs AKRO Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, ERAS is priced at $20.47, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas AKRO's P/E ratio is -14.57. In terms of profitability, ERAS's ROE is -0.77%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, ERAS is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check AKRO's competition here
ERAS vs ALPN Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, ERAS is priced at $20.47, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas ALPN's P/E ratio is -101.52. In terms of profitability, ERAS's ROE is -0.77%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, ERAS is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check ALPN's competition here
ERAS vs VKTX Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, VKTX has a market cap of 4.4B. Regarding current trading prices, ERAS is priced at $20.47, while VKTX trades at $38.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas VKTX's P/E ratio is -9.17. In terms of profitability, ERAS's ROE is -0.77%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, ERAS is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check VKTX's competition here
ERAS vs ACAD Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, ACAD has a market cap of 4.4B. Regarding current trading prices, ERAS is priced at $20.47, while ACAD trades at $25.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas ACAD's P/E ratio is 12.50. In terms of profitability, ERAS's ROE is -0.77%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, ERAS is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check ACAD's competition here
ERAS vs EWTX Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, EWTX has a market cap of 4.3B. Regarding current trading prices, ERAS is priced at $20.47, while EWTX trades at $39.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas EWTX's P/E ratio is -23.93. In terms of profitability, ERAS's ROE is -0.77%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, ERAS is more volatile compared to EWTX. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check EWTX's competition here
ERAS vs OPT Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, ERAS is priced at $20.47, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas OPT's P/E ratio is -1.52. In terms of profitability, ERAS's ROE is -0.77%, compared to OPT's ROE of +1.18%. Regarding short-term risk, ERAS is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check OPT's competition here
ERAS vs DNTH Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, DNTH has a market cap of 4.2B. Regarding current trading prices, ERAS is priced at $20.47, while DNTH trades at $100.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas DNTH's P/E ratio is -24.54. In terms of profitability, ERAS's ROE is -0.77%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, ERAS is more volatile compared to DNTH. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check DNTH's competition here
ERAS vs NAMSW Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, NAMSW has a market cap of 4.1B. Regarding current trading prices, ERAS is priced at $20.47, while NAMSW trades at $20.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas NAMSW's P/E ratio is -13.76. In terms of profitability, ERAS's ROE is -0.77%, compared to NAMSW's ROE of -0.30%. Regarding short-term risk, ERAS is more volatile compared to NAMSW. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check NAMSW's competition here
ERAS vs MRTX Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, ERAS is priced at $20.47, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas MRTX's P/E ratio is -4.82. In terms of profitability, ERAS's ROE is -0.77%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, ERAS is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check MRTX's competition here
ERAS vs DYN Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, DYN has a market cap of 3.9B. Regarding current trading prices, ERAS is priced at $20.47, while DYN trades at $23.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas DYN's P/E ratio is -7.39. In terms of profitability, ERAS's ROE is -0.77%, compared to DYN's ROE of -0.58%. Regarding short-term risk, ERAS is more volatile compared to DYN. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check DYN's competition here
ERAS vs NAMS Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, NAMS has a market cap of 3.9B. Regarding current trading prices, ERAS is priced at $20.47, while NAMS trades at $31.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas NAMS's P/E ratio is -20.94. In terms of profitability, ERAS's ROE is -0.77%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, ERAS is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for ERAS.Check NAMS's competition here
ERAS vs CPRX Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, ERAS is priced at $20.47, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas CPRX's P/E ratio is 11.33. In terms of profitability, ERAS's ROE is -0.77%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, ERAS is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check CPRX's competition here
ERAS vs RYZB Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, ERAS is priced at $20.47, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas RYZB's P/E ratio is -57.86. In terms of profitability, ERAS's ROE is -0.77%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, ERAS is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check RYZB's competition here
ERAS vs TLX Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, TLX has a market cap of 3.7B. Regarding current trading prices, ERAS is priced at $20.47, while TLX trades at $11.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas TLX's P/E ratio is -598.91. In terms of profitability, ERAS's ROE is -0.77%, compared to TLX's ROE of -0.02%. Regarding short-term risk, ERAS is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check TLX's competition here
ERAS vs CBAY Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, ERAS is priced at $20.47, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas CBAY's P/E ratio is -32.81. In terms of profitability, ERAS's ROE is -0.77%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, ERAS is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check CBAY's competition here
ERAS vs ELVN Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, ELVN has a market cap of 3.7B. Regarding current trading prices, ERAS is priced at $20.47, while ELVN trades at $51.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas ELVN's P/E ratio is -30.98. In terms of profitability, ERAS's ROE is -0.77%, compared to ELVN's ROE of -0.21%. Regarding short-term risk, ERAS is more volatile compared to ELVN. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check ELVN's competition here
ERAS vs TNGX Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, TNGX has a market cap of 3.7B. Regarding current trading prices, ERAS is priced at $20.47, while TNGX trades at $30.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas TNGX's P/E ratio is -35.72. In terms of profitability, ERAS's ROE is -0.77%, compared to TNGX's ROE of -0.42%. Regarding short-term risk, ERAS is more volatile compared to TNGX. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check TNGX's competition here
ERAS vs DNLI Comparison July 2026
ERAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERAS stands at 6.1B. In comparison, DNLI has a market cap of 3.6B. Regarding current trading prices, ERAS is priced at $20.47, while DNLI trades at $22.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERAS currently has a P/E ratio of -44.32, whereas DNLI's P/E ratio is -7.86. In terms of profitability, ERAS's ROE is -0.77%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, ERAS is more volatile compared to DNLI. This indicates potentially higher risk in terms of short-term price fluctuations for ERAS.Check DNLI's competition here